The stock analysis puts Novo's P/E well under the 21.7x pharma average and asks whether recent semaglutide data justify a higher price.
Recap by typeshit. Full story at Yahoo Finance.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
A 72-year-old patient says her side effects got far worse after her telehealth site switched compounders, as an estimated 5 million Americans now use compounded GLP-1s.
The Verge talks to nference's Venky Soundararajan, whose team says users wait about two months to tell doctors, and two thirds of records show no documented result.
Loading…